Tag: misses

Snap-On misses quarterly sales estimates on weak demand for power tools

 stock analyst  04/18/2024  0 Comments on Snap-On misses quarterly sales estimates on weak demand for power tools

(Reuters) – Snap-On missed Wall Street estimates for first-quarter sales on Thursday, as vehicle service and repair technicians bought fewer tools and equipment made by the company, offsetting steady demand for its products from auto dealerships.

Infosys shares fall as fourth-quarter revenue misses views

 stock analyst  04/18/2024  0 Comments on Infosys shares fall as fourth-quarter revenue misses views

(Updated – April 18, 2024 8:12 AM EDT) Infosys Limited (NS:INFY) shares plunged nearly 6% in early U.S. trading Thursday after the company missed analysts\’ fourth-quarter revenue estimates and issued downbeat guidance.

JB Hunt misses quarterly estimates on weaker-than-expected demand at biggest segment

 stock analyst  04/17/2024  0 Comments on JB Hunt misses quarterly estimates on weaker-than-expected demand at biggest segment

(Reuters) – U.S. trucking firm JB Hunt (NASDAQ:JBHT) Transport Services missed Wall Street estimates for first-quarter results on Tuesday, hurt by a decline in revenue in its biggest segment and pricing pressures at its brokerage business.

JB Hunt misses Q1 earnings, revenue forecasts

 stock analyst  04/17/2024  0 Comments on JB Hunt misses Q1 earnings, revenue forecasts

LOWELL, Ark. – J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) reported a decline in its first quarter 2024 earnings and revenue, missing analyst expectations. The company\’s earnings per share (EPS) came in at $1.22, falling short of the consensus estimate of $1.52 by $0.30. Revenue for the quarter was $2.94 billion, also below the analyst forecast of $3.12 billion.

J&J first-quarter revenue misses as Stelara sales disappoint

 stock analyst  04/16/2024  0 Comments on J&J first-quarter revenue misses as Stelara sales disappoint

(Reuters) -Johnson & Johnson reported quarterly revenue below analysts\’ estimates as sales from its blockbuster psoriasis drug Stelara, which is expected to face competition from biosimilar versions in some markets later this year, fell short of expectations.

Northern Trust misses Q1 estimates, shares fall slightly

 stock analyst  04/16/2024  0 Comments on Northern Trust misses Q1 estimates, shares fall slightly

CHICAGO – Northern Trust Corporation (NASDAQ:NTRS) disclosed its financial results for the first quarter of 2024, revealing earnings and revenue that fell short of Wall Street\’s expectations.